Trial record 1 of 1 for:    NCT01626664
Previous Study | Return to List | Next Study

KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01626664
Recruitment Status : Active, not recruiting
First Posted : June 25, 2012
Last Update Posted : December 22, 2017
Information provided by (Responsible Party):
Kyowa Kirin Pharmaceutical Development, Inc. ( Kyowa Hakko Kirin Pharma, Inc. )

Brief Summary:
The purpose of this study is to estimate the overall response rate of subjects with relapsed or refractory Adult T-cell Leukemia-Lymphoma (ATL).

Condition or disease Intervention/treatment Phase
Adult T-cell Leukemia-Lymphoma Biological: KW-0761 Drug: Pralatrexate Drug: gemcitabine plus oxaliplatin Drug: DHAP Phase 2

Detailed Description:
CCR4 expression in ATL patients has been demonstrated to be very high and has been associated with shorter survival compared with CCR4-negative patients. KW-0761, a monoclonal antibody targeted to CCR4, has been shown to be safe and tolerable in several clinical trials in subjects with a variety of T-cell malignancies, including ATL, mycosis fungoides and Sézary syndrome. The objective of this study is to estimate the overall response rate of KW-0761 for subjects with relapsed or refractory ATL.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 71 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)
Study Start Date : June 2012
Actual Primary Completion Date : August 2015
Estimated Study Completion Date : January 2018

Arm Intervention/treatment
Experimental: KW-0761
anti-CCR4 monoclonal antibody KW-0761 (mogamulizumab)
Biological: KW-0761
1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression
Other Names:
  • mogamulizumab
Active Comparator: investigator's choice
Comparator is investigator's choice of pralatrexate or gemcitabine plus oxaliplatin or DHAP
Drug: Pralatrexate
30 mg/m2 weekly for 3 weeks followed by 1 week of no therapy until progression
Other Name: Folotyn
Drug: gemcitabine plus oxaliplatin
gemcitabine 1000 mg/m2, followed by oxaliplatin 100 mg/m2 every 2 weeks until progression
Other Names:
  • Gemzar
  • Eloxatin
  • GemOx
Drug: DHAP
dexamethasone 40 mg on Day 1-4, cisplatin 100 mg/m2 on Day 1 followed by 2 doses of cytarabine 2000 mg/m2 every 4 weeks until progression
Other Names:
  • Decadron, Dexasone, Baycadron
  • Platinol
  • Depocyt, Ara-C

Primary Outcome Measures :
  1. Overall Response Rate [ Time Frame: every 8 weeks ]

Secondary Outcome Measures :
  1. progression free survival [ Time Frame: From date of randomization until the date of first documented progression, start of alternative therapy, or date of death from any cause, whichever came first, up to 36 months ]
  2. overall survival [ Time Frame: up to 36 months ]
  3. Quality of Life assessments [ Time Frame: up tp 36 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and female subjects ≥ 18 years of age
  • Confirmed diagnosis of ATL (excluding smoldering subtype)
  • Subjects must currently have evidence of disease in at least one of the following:

    • Lymph nodes
    • Extranodal masses
    • Spleen or liver
    • Skin
    • Peripheral blood
    • Bone marrow
  • Relapsed or refractory after at least one prior systemic therapy regimen for ATL;
  • Eastern Cooperative Oncology Group (ECOG) performance status score of ≤ 2 at study entry
  • resolution of all clinically significant toxic effects of prior cancer therapy to grade ≤1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0 (NCI-CTCAE, v.4.0)
  • adequate hematological, hepatic and renal function

Exclusion Criteria:

  • Smoldering subtype of ATL;
  • Lymphomatous or acute subtype subject with > 2 prior systemic therapy regimens and who has not achieved a response (CR or PR) or maintained stable disease for at least 12 weeks on last immediate prior therapy;
  • History of allogeneic transplant;
  • Autologous hematopoietic stem cell transplant within 90 days of study entry;
  • Untreated human immunodeficiency virus (HIV)
  • Has known hepatitis C. Patients who are hepatitis C antibody positive but are hepatitis C quantitative PCR negative may be enrolled;
  • Has hepatitis B based on PCR testing for hepatitis B virus DNA. Patients who are hepatitis B core antibody positive but PCR negative may be enrolled if placed on appropriate anti-hepatitis B virus prophylaxis prior to commencing treatment with KW-0761. Patients who are hepatitis B core antibody positive based on prior vaccination need not receive prophylaxis;
  • Have had a malignancy in the past two years except non-melanoma skin cancers, melanoma in situ, localized cancer of the prostate with current PSA < 0.1 µg/mL, treated thyroid cancer or cervical carcinoma in situ or ductal/lobular carcinoma in situ of the breast who is currently without evidence of disease;
  • Clinical evidence of central nervous system (CNS) involvement or metastasis. In subjects suspected of having CNS disease, an MRI of the brain and/or lumbar puncture should be done to confirm;
  • Psychiatric illness, disability or social situation that would compromise the subject's safety or ability to provide consent, or limit compliance with study requirements;
  • Significant uncontrolled intercurrent illness
  • Experienced allergic reactions to monoclonal antibodies or other therapeutic proteins;
  • Known active autoimmune diseases will be excluded (For example; Grave's disease; systemic lupus erythematosus; rheumatoid arthritis; Crohn's disease);
  • Is pregnant (confirmed by beta human chorionic gonadotrophin [β-HCG]) or lactating.
  • Prior treatment with KW-0761;
  • Initiation of treatment with systemic corticosteroids while on study is only permitted for acute and brief complications of underlying disease (e.g., hypercalcemia) or for treatment related side effects (e.g., including pre-medication for infusion reaction, nausea and vomiting). Subjects on systemic corticosteroids prior to enrollment must be off for 7 days before initiation of study treatment, unless specifically indicated for the treatment of hypercalcemia. (subjects may receive inhalation corticosteroids and replacement doses of systemic corticosteroids as needed);
  • Initiation of treatment with topical corticosteroids while on study is not permitted except to treat an acute rash. Subjects on a stable dose of medium or low potency topical corticosteroids for at least 4 weeks prior to Pre-treatment Visit may continue use at the same dose, although the investigator should attempt to taper the use to lowest dose tolerable;
  • Have had interferon-α and/or zidovudine within 1 week, or anti-neoplastic chemotherapy, radiation, immunotherapy, or investigational medications within 2 weeks of first study treatment;
  • Subjects on any immunomodulatory drug. Subjects on any immunomodulatory drug within 4 weeks of their first dose of KW-0761 are also excluded.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01626664

United States, California
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90048
United States, Florida
University of Miami / Sylvester Comprehensive Cancer Center
Miami, Florida, United States, 33136
United States, Illinois
Northwestern University
Chicago, Illinois, United States, 60611
United States, Maryland
National Cancer Institute
Bethesda, Maryland, United States, 20892
United States, Missouri
Washington University School of Medicine
Saint Louis, Missouri, United States, 63110
United States, New Jersey
Hackensack University Medical Center
Hackensack, New Jersey, United States, 07601
United States, New York
Montefiore Medical Center
Bronx, New York, United States, 10467
Memorial Sloan Kettering
New York, New York, United States, 10021
Columbia Presbyterian
New York, New York, United States, 10032
Weill Cornell Medical College
New York, New York, United States, 10065
Cliniques Universitaires Saint-Luc
Bruxelles, Belgium, 1200
Hospital Universitario Professor Edgard Santos- UFBA
Salvador, Bahia, Brazil, 40110-060
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Sao Paulo- SP, Brazil, CEP 05403-000
CHU de Fort de France
Fort De France Cedex, France, BP 632 97261
Hospital Necker
Paris, France, 75743
Hospital Nacional Edgardo Rebagliati Martins
Lima, Peru, Lima11
Instituto Oncologico Miraflores
Lima, Peru, Lima18
United Kingdom
Guy's Hospital
London, United Kingdom, SE1 9RT
Imperial College
London, United Kingdom, W2 1PG
Sandwell General Hospital
West Midlands, United Kingdom, B71 4HJ
Sponsors and Collaborators
Kyowa Hakko Kirin Pharma, Inc.
Study Director: Michael Kurman, MD Kyowa Hakko Kirin Pharma, Inc.

Responsible Party: Kyowa Hakko Kirin Pharma, Inc. Identifier: NCT01626664     History of Changes
Other Study ID Numbers: PROTOCOL 0761-009
First Posted: June 25, 2012    Key Record Dates
Last Update Posted: December 22, 2017
Last Verified: December 2017

Keywords provided by Kyowa Kirin Pharmaceutical Development, Inc. ( Kyowa Hakko Kirin Pharma, Inc. ):
Adult T cell Leukemia-Lymphoma (ATL)

Additional relevant MeSH terms:
Leukemia, T-Cell
Leukemia-Lymphoma, Adult T-Cell
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, Lymphoid
Antibodies, Monoclonal
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Enzyme Inhibitors
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs